Primary Care Clinics in Stonewall, LA Accepting Medicare
3 Primary Care Clinics found. Showing 1 - 3
 Casse Community Health - Stonewall Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Medicare Enrolled Practice Location: 149 Stonecreek Dr., Stonewall, LA 71078 Phone: 318-688-3350 Fax: 318-688-3655 |
Magnolia Family Medicine, Llc Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 324 Plantation Hills Blvd, Stonewall, LA 71078 Phone: 318-220-6879 |
Council For Advancement Of Social Service And Education Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: 149 Stonecreek Dr., Stonewall, LA 71078 Phone: 318-688-3350 |
News Archive
Findings on cell working could lead to test and therapy for kidney failure caused by E. coli
New findings by St. Michael's researchers about the way cells work could lead to a test and therapy for kidney failure caused by E. coli
Patients beginning therapy on popular osteoporosis drugs discontinue treatment within 6 months: Report
According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.
FDA approval provides targeted treatment option for patients with rare DMD mutation
Today, the U.S. Food and Drug Administration granted approval for Amondys 45 (casimersen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping (Exons are pieces of DNA that provide information for making proteins in a person's genome).
Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer
Sanofi-aventis announced today results from a Phase 3 trial which demonstrated cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy.
› Verified 4 days ago